within Pharmacolibrary.Drugs.ATC.D;

model D07AC03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 1.6666666666666667,
    adminDuration  = 600,
    adminMass      = 0.0025,
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Desoximetasone is a potent synthetic corticosteroid used topically to reduce inflammation and suppress immune responses in skin conditions such as psoriasis, dermatitis, and eczema. It is approved for use in several countries, including the United States, primarily as a prescription topical medication.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic model for desoximetasone as a topical or systemic drug was found. The following values represent estimated parameters based on topical corticosteroid pharmacokinetics and general knowledge of corticosteroids.</p><h4>References</h4><ol><li><p>Shah, P, et al., &amp; Michniak-Kohn, B (2021). Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone. <i>International journal of molecular sciences</i> 22(4) –. DOI:<a href=&quot;https://doi.org/10.3390/ijms22041535&quot;>10.3390/ijms22041535</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33546426/&quot;>https://pubmed.ncbi.nlm.nih.gov/33546426</a></p></li><li><p>Matharoo, NS, et al., &amp; Michniak-Kohn, B (2023). A Comparative Evaluation of Desoximetasone Cream and Ointment Formulations Using Experiments and In Silico Modeling. <i>International journal of molecular sciences</i> 24(20) –. DOI:<a href=&quot;https://doi.org/10.3390/ijms242015118&quot;>10.3390/ijms242015118</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37894801/&quot;>https://pubmed.ncbi.nlm.nih.gov/37894801</a></p></li><li><p>Borelli, C, et al., &amp; Korting, HC (2008). Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay. <i>Skin pharmacology and physiology</i> 21(3) 181–187. DOI:<a href=&quot;https://doi.org/10.1159/000131082&quot;>10.1159/000131082</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18523415/&quot;>https://pubmed.ncbi.nlm.nih.gov/18523415</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D07AC03;
